TYPE 3 DIABETES: THE MOLECULAR LINK BETWEEN INSULIN RESISTANCE AND NEURODEGENERATION
Keywords:
Keywords: Type 3 diabetes, Alzheimer’s disease, brain insulin resistance, amyloid-beta, tau pathology, neurodegeneration, intranasal insulinAbstract
Abstract
Type 3 diabetes (T3D) is a proposed term for Alzheimer’s Disease (AD) that
represents a form of diabetes that selectively involves the brain. This condition is
characterized by brain-specific insulin resistance and insulin deficiency, which triggers
a cascade of neurodegenerative processes. This review explores the pathophysiology,
clinical presentation, and emerging therapeutic landscape for T3D.
References
References
1. Baker, L.D., et al. (2011). “Insulin resistance and Alzheimer-like reductions in
regional cerebral glucose metabolism.” Archives of Neurology, 68(1), 51–57.
2. Cercato, C., et al. (2019). “The role of physical exercise in Type 3 Diabetes.”
Frontiers in Endocrinology, 10, 729.
3. Craft, S., & Watson, G.S. (2004). “Insulin and neurodegeneration.” Lancet
Neurology, 3(3), 169–178.
4. Craft, S., et al. (2012). “Intranasal insulin therapy for Alzheimer disease and
amnestic mild cognitive impairment: a pilot clinical trial.” Archives of Neurology,
69(1), 29–38.
5. de la Monte, S.M. (2014). “Type 3 diabetes is the primary cause of Alzheimer’s
disease.” Journal of Diabetes Science and Technology, 8(6), 1185–1192.
6. de la Monte, S.M., & Wands, J.R. (2008). “Alzheimer’s Disease is Type 3
Diabetes—Evidence Reviewed.” Journal of Diabetes Science and Technology,
2(6), 1101–1113.
7. Gejl, M., et al. (2016). “In Alzheimer’s Disease, 6-Month Treatment with GLP-1
Analog Prevents Decline of Cerebral Glucose Metabolism.” Frontiers in Aging
Neuroscience, 8, 108.
8. Kapogiannis, D., et al. (2015). “Dysfunctionally phosphorylated type 1 insulin
receptor substrate in neural-derived blood exosomes of preclinical Alzheimer’s
disease.” FASEB Journal, 29(2), 589–596.
9. Koenig, A.M., et al. (2017). “Effects of the Insulin Sensitizer Metformin on AD
Biomarkers: A Randomized, Placebo-Controlled Crossover Trial.” Contemporary
Clinical Trials, 60, 20–23.
10. Steen, E., et al. (2005). “Impaired insulin and insulin-like growth factor expression
and signaling mechanisms in Alzheimer’s disease—is this type 3 diabetes?” Journal
of Alzheimer’s Disease, 7(1), 63–80.
11. Talbot, K., et al. (2012). “Demonstrated brain insulin resistance in Alzheimer’s
disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and
cognitive decline.” Journal of Clinical Investigation, 122(4), 1316–1338.
